ERBB3 and cancer: In particular, ErbB3 has been linked to the migratory behavior and metastasis of cancer cells and is responsible for acquired resistance to anti-EGFR therapies (Gaborit et al., 2016; Pradeep et al., 2014; Smirnova et al., 2012; Yoshioka et al., 2010; Tiwary et al., 2014).